> Detailanzeige

Rohani, Roxane; Scheetz, Marc H; Donnelly, Helen K; Donayre, Alvaro; Kang, Mengjia; Diaz, Estefani; Dedicatoria, Kay; Hauser, Alan R; Ozer, Egon A; Nozick, Sophia; Qi, Chao; Pawlowski, Anna E; Neely, Michael N; Misharin, Alexander V; Wunderink, Richard G; Rhodes, Nathaniel J; Abdala-Valencia, Hiam; Alexander, Michael J; Arnold, Jason M; Bailey, Joseph Isaac; Bartom, Elizabeth T; Bharat, Ankit; Bolig, Thomas; Borkowski, Nicole; [...]

Individual target pharmacokinetic/pharmacodynamic attainment rates among meropenem-treated patients admitted to the ICU with hospital-acquired pneumonia

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Individual target pharmacokinetic/pharmacodynamic attainment rates among meropenem-treated patients admitted to the ICU with hospital-acquired pneumonia
  • Beteiligte: Rohani, Roxane; Scheetz, Marc H; Donnelly, Helen K; Donayre, Alvaro; Kang, Mengjia; Diaz, Estefani; Dedicatoria, Kay; Hauser, Alan R; Ozer, Egon A; Nozick, Sophia; Qi, Chao; Pawlowski, Anna E; Neely, Michael N; Misharin, Alexander V; Wunderink, Richard G; Rhodes, Nathaniel J; Abdala-Valencia, Hiam; Alexander, Michael J; Arnold, Jason M; Bailey, Joseph Isaac; Bartom, Elizabeth T; Bharat, Ankit; Bolig, Thomas; Borkowski, Nicole; [...]
  • Erschienen: Oxford University Press (OUP), 2022
  • Erschienen in: Journal of Antimicrobial Chemotherapy, 77 (2022) 11, Seite 2956-2959
  • Sprache: Englisch
  • DOI: 10.1093/jac/dkac245
  • ISSN: 0305-7453; 1460-2091
  • Schlagwörter: Infectious Diseases ; Pharmacology (medical) ; Pharmacology ; Microbiology (medical)
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:title>Abstract</jats:title> <jats:sec> <jats:title>Objectives</jats:title> <jats:p>Critical illness reduces β-lactam pharmacokinetic/pharmacodynamic (PK/PD) attainment. We sought to quantify PK/PD attainment in patients with hospital-acquired pneumonia.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods</jats:title> <jats:p>Meropenem plasma PK data (n = 70 patients) were modelled, PK/PD attainment rates were calculated for empirical and definitive targets, and between-patient variability was quantified [as a coefficient of variation (CV%)].</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>Attainment of 100% T&amp;gt;4×MIC was variable for both empirical (CV% = 92) and directed (CV% = 33%) treatment.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions</jats:title> <jats:p>Individualization is required to achieve suggested PK/PD targets in critically ill patients.</jats:p> </jats:sec>
  • Zugangsstatus: Freier Zugang